chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, Facial pain, Headache, Immunisation, Insomnia
Clinical narrative: Headache; Nausea; Running a fever / temp is 100 degrees; Severe muscle pain in whole body; Tingling in arms and legs; Neck hurts; Jaw tight; Pain behind eyes; Having trouble keeping food down; Depressed; Crying; Face pain; Shaking; Back pain; Unable to stay asleep; Throwing up; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2590) via an unspecified route of administration in the right arm on 28Oct2021 at 15:45 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included narcolepsy and depression. The patient was allergic to powder on latex gloves. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received cefalexin (CEPHALEXIN) and escitalopram oxalate (LEXAPRO) and experienced drug allergy. The patient previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0172) via an unspecified route of administration in the right arm on 30Apr2021 at 15:30 (at the age of 45-years-old) and also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 09Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 29Oct2021 at 12:00, the patient experienced headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 29Oct2021, the patient underwent body temperature test and the result was 100 degrees (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up were unknown at the time of this report.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness, Myalgia, Nausea, Neck pain, Paraesthesia
Clinical narrative: Headache; Nausea; Running a fever / temp is 100 degrees; Severe muscle pain in whole body; Tingling in arms and legs; Neck hurts; Jaw tight; Pain behind eyes; Having trouble keeping food down; Depressed; Crying; Face pain; Shaking; Back pain; Unable to stay asleep; Throwing up; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2590) via an unspecified route of administration in the right arm on 28Oct2021 at 15:45 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included narcolepsy and depression. The patient was allergic to powder on latex gloves. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received cefalexin (CEPHALEXIN) and escitalopram oxalate (LEXAPRO) and experienced drug allergy. The patient previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0172) via an unspecified route of administration in the right arm on 30Apr2021 at 15:30 (at the age of 45-years-old) and also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 09Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 29Oct2021 at 12:00, the patient experienced headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 29Oct2021, the patient underwent body temperature test and the result was 100 degrees (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up were unknown at the time of this report.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Tremor, Vomiting
Clinical narrative: Headache; Nausea; Running a fever / temp is 100 degrees; Severe muscle pain in whole body; Tingling in arms and legs; Neck hurts; Jaw tight; Pain behind eyes; Having trouble keeping food down; Depressed; Crying; Face pain; Shaking; Back pain; Unable to stay asleep; Throwing up; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2590) via an unspecified route of administration in the right arm on 28Oct2021 at 15:45 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included narcolepsy and depression. The patient was allergic to powder on latex gloves. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received cefalexin (CEPHALEXIN) and escitalopram oxalate (LEXAPRO) and experienced drug allergy. The patient previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0172) via an unspecified route of administration in the right arm on 30Apr2021 at 15:30 (at the age of 45-years-old) and also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 09Apr2021 at 16:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 29Oct2021 at 12:00, the patient experienced headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 29Oct2021, the patient underwent body temperature test and the result was 100 degrees (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, nausea, running a fever, severe muscle pain in whole body, tingling in arms and legs, neck hurts, jaw tight, pain behind eyes, temperature was 100 degrees, having trouble keeping food down, depressed, crying, face pain, shaking, back pain, unable to stay asleep and throwing up were unknown at the time of this report.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia, Blood test
Clinical narrative: Loss of hair (the volume of hair loss was a lot); This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00(at the age of 58-years-old) as a single dose for COVID-19 immunisation. The medical history included COVID-19. The patient's known allergies were reported as not applicable. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, the patient experienced loss of hair (the volume of hair loss was a lot). On an unknown date in 2021, the patient underwent blood test and the result was not reported. The adverse event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the reported event included unspecified medication prescribed by the doctor. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event loss of hair  was resolved on an unknown date in 2021.The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10Apr2021 at 08:00(at the age of 58-years-old) as a single dose for COVID-19 immunisation.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Erythema, Immunisation, Rash, Rash erythematous, Rash macular
Clinical narrative: Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas.; Some parts are blotchy.; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach and upper legs/groin areas. Some parts are blotchy. It is a little warm(3/10).; A third (booster) dose of BNT162b2 was administered; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 320398D) via an unspecified route of administration in the left arm on 28Oct2021 at 14:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included fexofenadine hydrochloride/pseudoephedrine hydrochloride (ALLEGRA-D 24 HOUR), colecalciferol (VITAMIN D3) and triamcinolone acetonide (NASACORT 24 HOUR); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 24Mar2021 at 14:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 15Apr2021 at 14:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced drug allergy. On 30Oct2021 at 12:30 AM, the patient experienced rash/skin redness which was similar to the sunburn on neck, chest, back, sides, stomach and upper legs/groin areas, some parts were blotchy and it was a little warm (3/10). It was reported that it did not itch and was not painful. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach and upper legs/groin areas, some parts were blotchy and it was a little warm (3/10) was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Skin warm
Clinical narrative: Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach, and upper legs/groin areas.; Some parts are blotchy.; Rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach and upper legs/groin areas. Some parts are blotchy. It is a little warm(3/10).; A third (booster) dose of BNT162b2 was administered; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 320398D) via an unspecified route of administration in the left arm on 28Oct2021 at 14:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included fexofenadine hydrochloride/pseudoephedrine hydrochloride (ALLEGRA-D 24 HOUR), colecalciferol (VITAMIN D3) and triamcinolone acetonide (NASACORT 24 HOUR); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 24Mar2021 at 14:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 15Apr2021 at 14:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced drug allergy. On 30Oct2021 at 12:30 AM, the patient experienced rash/skin redness which was similar to the sunburn on neck, chest, back, sides, stomach and upper legs/groin areas, some parts were blotchy and it was a little warm (3/10). It was reported that it did not itch and was not painful. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash/skin redness, similar to sunburn on neck, chest, back, sides, stomach and upper legs/groin areas, some parts were blotchy and it was a little warm (3/10) was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo positional
Clinical narrative: Benign paroxysmal positional vertigo (BPPV); This is a spontaneous report from a non-contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 12Aug2021 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Aug2021, the patient experienced benign paroxysmal positional vertigo (BPPV). The event resulted in doctor or other healthcare professional office/ clinic visit. Therapeutic measures were taken as a result of the event and the treatment included vestibular physical therapy. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event benign paroxysmal positional vertigo (BPPV) was resolving at the time of this report.   No follow-up attempts are possible; information on lot/batch number cannot be obtained. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Pyrexia
Clinical narrative: Fever; Chills; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 02212022) via an unspecified route of administration in the left arm on 29Oct2021 at 09:15 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included minocycline (MANUFACTURER UNKNOWN); taken for unknown indication from an unknown date and unknown if ongoing. On 29Oct2021 at 22:00, the patient had fever and chills for about 5 hours. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever and chills was resolved on 30Oct2021 at 03:00.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Depression, Fatigue, Feeling abnormal, Pyrexia
Clinical narrative: Brain fog; Depression; Fatigue; Weak; Fever; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on an unknown date in 2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included hepatitis C (Hep C). The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. Concomitant medication included influenza vaccine (MANUFACTURER UNKNOWN) on 20Sep2021 for immunization. On 24Oct2021, the patient experienced brain fog, depression, fatigue, weak and fever. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with paracetamol (TYLENOL), dextromethorphan hydrobromide, guaifenesin (MUCINEX DM), plenty of water and sleep. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events brain fog, depression, fatigue, weak and fever was resolved on an unknown date in Oct2021.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Immunisation, Nausea, Vaccination site pain
Clinical narrative: Pain at injection site; Nausea; Chills; A third (booster) dose of BNT162b2 was administered; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration on 27Oct2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 28Oct2021, the patient experienced nausea, chills and pain at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, chills and pain at injection site was unknown at the time of this report.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Immunisation, SARS-CoV-2 test, Sensory disturbance, Vision blurred
Clinical narrative: A third (booster) dose of BNT162b2 was administered; Sensation on my legs; Eyes sights blurry; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2589) via an unspecified route of administration in the left arm on 27Oct2021 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine (MANUFACTURER UNKNOWN) on 10Oct2021 for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration in the left arm on 16Mar2021 (at the age of 45-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FN6207) via an unspecified route of administration in the left arm on an unknown date in Apr2021 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient received flu vaccine within four weeks prior to the COVID-19 vaccine. On an unknown date in Oct2021, the patient experienced sensation on his legs and eyes sights blurry. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in Oct2021, the patient underwent polymerase chain reaction (PCR) test via nasal swab and the result was negative. The clinical outcome of the events sensation on his legs blurry and eyes sights blurry was unknown at the time of this report.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Fatigue, Feeling hot, Immunisation, Increased upper airway secretion
Clinical narrative: Booster induced sore arm the next day. "I" woke up and felt some soreness go down "my" whole arm, like nerve pain but it was not extremely painful.; Armpit it also sore and tender to touch.; Also feeling a little warm; Feel kind of sick; "I" also feel tired; "I" have mucus buildup in "my" throat; Booster dose; This is a spontaneous report from a contactable other healthcare professional, the patient. A 24-year-old non-pregnant female patient received third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0217) via an intramuscular route of administration in the left arm on 28Oct2021 at 10:45(at the age of 24-years-old) as a single dose for COVID-19 immunisation. The medical history included polycystic ovarian syndrome (PCOS). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included metformin (MANUFACTURER UNKNOWN) before booster shot from an unknown date for an unknown indication and unspecified birth control throughout all shots from an unknown date and all were unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an intramuscular route of administration on 25Jan2021 (at the age of 23-years-old) and received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an intramuscular route of administration on 15Feb2021 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. The patient also took previously amoxicillin(MANUFACTURER UNKNOWN) on an unknown date and experienced allergy. On 29Oct2021, the next day, the patient experienced booster induced sore arm and woke up and felt some soreness went down whole arm, like nerve pain but it was not extremely painful. The armpit also sore and tender to touch. The patient also felt a little warm, felt kind of sick, felt tired and she noticed she had mucus buildup in her throat. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events booster induced sore arm the next day and woke up and felt some soreness went down whole arm, like nerve pain but it was not extremely painful, armpit also sore and tender to touch, also felt a little warm, felt kind of sick, felt tired, mucus buildup in throat were resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Pain in extremity
Clinical narrative: Booster induced sore arm the next day. "I" woke up and felt some soreness go down "my" whole arm, like nerve pain but it was not extremely painful.; Armpit it also sore and tender to touch.; Also feeling a little warm; Feel kind of sick; "I" also feel tired; "I" have mucus buildup in "my" throat; Booster dose; This is a spontaneous report from a contactable other healthcare professional, the patient. A 24-year-old non-pregnant female patient received third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0217) via an intramuscular route of administration in the left arm on 28Oct2021 at 10:45(at the age of 24-years-old) as a single dose for COVID-19 immunisation. The medical history included polycystic ovarian syndrome (PCOS). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included metformin (MANUFACTURER UNKNOWN) before booster shot from an unknown date for an unknown indication and unspecified birth control throughout all shots from an unknown date and all were unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an intramuscular route of administration on 25Jan2021 (at the age of 23-years-old) and received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an intramuscular route of administration on 15Feb2021 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. The patient also took previously amoxicillin(MANUFACTURER UNKNOWN) on an unknown date and experienced allergy. On 29Oct2021, the next day, the patient experienced booster induced sore arm and woke up and felt some soreness went down whole arm, like nerve pain but it was not extremely painful. The armpit also sore and tender to touch. The patient also felt a little warm, felt kind of sick, felt tired and she noticed she had mucus buildup in her throat. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events booster induced sore arm the next day and woke up and felt some soreness went down whole arm, like nerve pain but it was not extremely painful, armpit also sore and tender to touch, also felt a little warm, felt kind of sick, felt tired, mucus buildup in throat were resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Immunisation, Malaise, Musculoskeletal chest pain, Nausea
Clinical narrative: A third (booster) dose of BNT162b2 was administered; Very sore left arm; Entire upper arm swollen; Left side of torso sore down through the ribs/ body aches; Left side of torso sore down through the ribs; Felt ill all weekend plus Monday; Nausea; Headache; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 30145BA) via an unspecified route of administration in the left arm on 22Oct2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure (BP), cholesterol and chronic kidney disease (CKD). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine (MANUFACTURER UNKNOWN) via an unspecified route of administration in the left arm on 07Oct2021 for an unknown indication, esomeprazole magnesium (NEXIUM 24HR), mometasone furoate (MANUFACTURER UNKNOWN) and fexofenadine hydrochloride (FEXOFENADIN); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 11Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 64-years-old)  as a single dose for COVID-19 immunisation. The patient received flu vaccine within four weeks prior to the COVID-19 vaccine. On 22Oct2021, the patient experienced very sore left arm, entire upper arm swollen, left side of torso sore down through the ribs, also felt ill all weekend plus Monday after the shot on Friday, nausea, headache, body aches and fever. The patient reported that she still felt swollen and sore a week later. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sore left arm, entire upper arm swollen, left side of torso sore down through the ribs, also felt ill all weekend plus Monday after the shot on Friday, nausea, headache, body aches and fever were not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Peripheral swelling, Pyrexia
Clinical narrative: A third (booster) dose of BNT162b2 was administered; Very sore left arm; Entire upper arm swollen; Left side of torso sore down through the ribs/ body aches; Left side of torso sore down through the ribs; Felt ill all weekend plus Monday; Nausea; Headache; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 30145BA) via an unspecified route of administration in the left arm on 22Oct2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure (BP), cholesterol and chronic kidney disease (CKD). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine (MANUFACTURER UNKNOWN) via an unspecified route of administration in the left arm on 07Oct2021 for an unknown indication, esomeprazole magnesium (NEXIUM 24HR), mometasone furoate (MANUFACTURER UNKNOWN) and fexofenadine hydrochloride (FEXOFENADIN); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 11Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 64-years-old)  as a single dose for COVID-19 immunisation. The patient received flu vaccine within four weeks prior to the COVID-19 vaccine. On 22Oct2021, the patient experienced very sore left arm, entire upper arm swollen, left side of torso sore down through the ribs, also felt ill all weekend plus Monday after the shot on Friday, nausea, headache, body aches and fever. The patient reported that she still felt swollen and sore a week later. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sore left arm, entire upper arm swollen, left side of torso sore down through the ribs, also felt ill all weekend plus Monday after the shot on Friday, nausea, headache, body aches and fever were not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Immunisation, Myalgia
Clinical narrative: Chills; Muscle pain; Diarrhea; Administration date 27Oct2021 at 11:00, dose number=3; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the right arm on 27Oct2021 at 11:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer diagnosed in 2019. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included anastrozole (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN); all taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration in the right arm on 24Feb2021 (at the age of 50-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration in the right arm on 17Mar2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient previously received influenza vaccine (MANUFACTURER UNKNOWN) on 28Sep2021 (at the age of 50-years-old) for immunization. On 27Oct2021 at 11:00, the patient had "administration date 27Oct2021 at 11:00, dose number=3". On 28Oct2021 at 14:00, the patient experienced chills, muscle pain and diarrhea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of events chills, muscle pain and diarrhea and included treatment with ibuprofen (ADVIL). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, muscle pain and diarrhea was resolved on an unknown date in Oct2021. The clinical outcome of the event "administration date 27Oct2021 at 11:00, dose number=3" was unknown at the time of this report.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Immunisation, Malaise
Clinical narrative: EXTREME MALAISE; WEAKNESS; DIZZYNESS; Booster dose taken on 27Oct2021 at 14:30; This is a spontaneous report from a contactable consumer, the patient. A 76-year-old non-pregnant female patient received third (BOOSTER) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: F63527) via an unspecified route of administration in the left arm on 27Oct2021 at 14:30 (at the age of 76-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD), diastolic dysfunction, severe neuropathy bilateral lower extremities (BLE), depression, high blood pressure (B/P) and stroke minor. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified regular concomitant medications within two weeks of vaccination. The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 30Mar2021 at 13:15 (at the age of 75-years-old) and first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 05Mar2021 at 14:00 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. The patient previously received simvastatin (MANUFACTURER UNKNOWN) on an unknown date for unknown indication and experienced drug allergy. On 28Oct2021 at 07:00, the patient experienced extreme malaise, weakness and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme malaise, weakness and dizziness were resolving at the time of this report.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site mass, Vaccination site pain, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Hard lump under skin 3cm medial from injection site. 3.6 cm x 4.1 cm red, itchy, painful to touch, warm to touch; Hard lump under skin 3cm medial from injection site. 3.6 cm x 4.1 cm red, itchy, painful to touch, warm to touch; Hard lump under skin 3cm medial from injection site. 3.6 cm x 4.1 cm red, itchy, painful to touch, warm to touch; Hard lump under skin 3cm medial from injection site. 3.6 cm x 4.1 cm red, itchy, painful to touch, warm to touch; Hard lump under skin 3cm medial from injection site. 3.6 cm x 4.1 cm red, itchy, painful to touch, warm to touch; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8841) via an unspecified route of administration in the left arm on 27Oct2021 at 19:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included levonorgestrel (MIRENA IUD), vaccinium macrocarpon fruit (THERACRAN ONE), probiotic (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: PAA173696) via an unspecified route of administration in the left arm on 06Oct2021 at 19:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. On an unknown date in Oct2021 at 11:00, the patient experienced hard lump under skin 3 cm medial from injection site, 3.6 cm x 4.1 cm, red, itchy, painful and warm to touch. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events hard lump under skin 3 cm medial from injection site, 3.6 cm x 4.1 cm red, itchy, painful and warm to touch was not resolved at the time of this report.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Immunisation, Myalgia, Neck pain, Vaccination site pain
Clinical narrative: muscle in the exact area became very sore and tender to touch,; Booster; Soreness from the injection / It is now over three weeks since being vaccinated, and, while I can move the arm without trouble, it continues to be sore, aching, and tender in the same place; soreness now radiating to my upper shoulder and neck.; soreness now radiating to my upper shoulder and neck.; This is a spontaneous report from a non-contactable consumer, the patient. A 68-year-old non-pregnant female patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Oct2021 at 14:30 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included sicca syndrome, celiac sprue, allergy to sulfa and cow's milk. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication included levothyroxine sodium (LEVOXYL) for unspecified indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Feb2021 at 15:00 and received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11Mar2021 at 15:00; both as a single dose for COVID-19 immunisation. On 11Oct2021, about a week after initial soreness from the injection subsided, muscle in the exact area became very sore, tender to touch without redness or swelling. It was three weeks (at the time of reporting) since patient got vaccinated and while patient could move the arm without trouble, it continued to be sore, aching, and tender in the same place with soreness radiating to upper shoulder and neck. The events had not resulted in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events soreness from the injection, muscle in the exact area became very sore, tender to touch without redness or swelling, soreness radiating to upper shoulder and soreness radiating to neck was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Chills, Pain in extremity, Peripheral coldness, Peripheral swelling
Clinical narrative: Poor blood circulation in leg and feet; Bottom of feet turn pinkish color then turn purple; Very pain full and swallowing at the bottom of foot; Very pain full and swallowing at the bottom of foot; Very cold feet; Unrecognizable symptoms of chill; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 18Mar2021 at 13:15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 25Feb2021 at 13:30 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 00:00, after vaccine the patient had poor blood circulation in her leg and feet. Her bottom of feet turned pinkish color then turn purple, very pain full and "swallowing" at the bottom of foot. She had very cold feet and unrecognizable symptoms of chill. On an unknown date in 2021, the patient underwent blood test and the result was unknown. The events resulted in doctor/other health care professional office/clinic visit. Therapeutic measures were taken as a result of the events included "so many" blood test (unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events poor blood circulation in leg and feet, bottom of feet turns pinkish color then turn purple, very pain full and swallowing at the bottom of foot, very cold feet and unrecognizable symptoms of chill was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.